Carlsmed Statistics
Total Valuation
Carlsmed has a market cap or net worth of $345.82 million. The enterprise value is $332.98 million.
Important Dates
The next confirmed earnings date is Thursday, November 6, 2025, after market close.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Carlsmed has 26.58 million shares outstanding.
| Current Share Class | 26.58M |
| Shares Outstanding | 26.58M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +6.75% |
| Owned by Insiders (%) | 10.98% |
| Owned by Institutions (%) | 1.95% |
| Float | 9.70M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.47 |
| Forward PS | 6.30 |
| PB Ratio | 13.59 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 8.70 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.87, with a Debt / Equity ratio of 0.69.
| Current Ratio | 4.87 |
| Quick Ratio | 4.55 |
| Debt / Equity | 0.69 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -16.46 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -56.40% |
| Revenue Per Employee | $430,000 |
| Profits Per Employee | -$294,427 |
| Employee Count | 89 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 13.68 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 44.77 |
| Average Volume (20 Days) | 69,012 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Carlsmed had revenue of $38.27 million and -$26.20 million in losses. Loss per share was -$6.13.
| Revenue | 38.27M |
| Gross Profit | 28.33M |
| Operating Income | -24.70M |
| Pretax Income | -25.03M |
| Net Income | -26.20M |
| EBITDA | -24.52M |
| EBIT | -24.70M |
| Loss Per Share | -$6.13 |
Full Income Statement Balance Sheet
The company has $33.47 million in cash and $17.71 million in debt, giving a net cash position of $15.77 million or $0.59 per share.
| Cash & Cash Equivalents | 33.47M |
| Total Debt | 17.71M |
| Net Cash | 15.77M |
| Net Cash Per Share | $0.59 |
| Equity (Book Value) | 25.66M |
| Book Value Per Share | -18.04 |
| Working Capital | 36.71M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$26.98 million and capital expenditures -$523,000, giving a free cash flow of -$27.50 million.
| Operating Cash Flow | -26.98M |
| Capital Expenditures | -523,000 |
| Free Cash Flow | -27.50M |
| FCF Per Share | -$1.03 |
Full Cash Flow Statement Margins
Gross margin is 74.02%, with operating and profit margins of -64.53% and -65.40%.
| Gross Margin | 74.02% |
| Operating Margin | -64.53% |
| Pretax Margin | -65.40% |
| Profit Margin | -65.40% |
| EBITDA Margin | -64.08% |
| EBIT Margin | -64.53% |
| FCF Margin | n/a |
Dividends & Yields
Carlsmed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -7.51% |
| FCF Yield | -7.89% |
Analyst Forecast
The average price target for Carlsmed is $18.33, which is 40.89% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $18.33 |
| Price Target Difference | 40.89% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Carlsmed has an Altman Z-Score of -2.18. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.18 |
| Piotroski F-Score | n/a |